TICKERNERD
Menu
MEDMEDConsumer Cyclical · Personal Services

MED Stock Forecast: Medifast, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$12
+0.42% on the day

The 1 Wall Street analysts covering Medifast, Inc. hold a median 12-month price target of $12 — +0.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$133.6M
Ticker Nerd rank
46 / 100
Median analyst target
$12
Analysts covering
1
Total return, dividends reinvested
1W
+4.9%
1M
+24.0%
YTD
+12.4%
1Y
−16.0%
From 52W high
−17.6%
From 52W low
+27.0%
$9
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medifast, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Revisions
87
Size
73
Quality
43
Volatility
35
Momentum
32
Growth
30
Issuance
28
Value
5

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$9$10$11$12$13$14$15Oct 25Jan 26Apr 26Jul 26MEDHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $12Median $12High $12

The green dot is the last close — the median target sits 0.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Feb 2026Stephens & Co.MaintainsEqual-Weight$15 → $12
19 Feb 2026Stephens & Co.MaintainsEqual-Weight—
19 Feb 2025DA DavidsonMaintainsNeutral—
5 Nov 2024DA DavidsonUpgradeNeutral—
22 July 2024DA DavidsonMaintainsUnderperform—
5 June 2024DA DavidsonDowngradeUnderperform—
30 Apr 2024DA DavidsonMaintainsNeutral—
21 Feb 2024DA DavidsonMaintainsNeutral—
13 Oct 2023Stephens & Co.InitiatesEqual-Weight—
8 Aug 2023DA DavidsonMaintainsNeutral—
31 July 2023DA DavidsonMaintainsNeutral—
2 May 2023DA DavidsonMaintainsNeutral—
22 Feb 2023DA DavidsonMaintainsNeutral—
4 Nov 2022DA DavidsonDowngradeNeutral—
4 Aug 2022DA DavidsonMaintainsBuy—
4 Aug 2022JefferiesDowngradeHold—
2 June 2022DA DavidsonMaintainsBuy—
24 Feb 2022DA DavidsonMaintainsBuy—
8 Nov 2021DA DavidsonMaintainsBuy—
5 May 2021DA DavidsonMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MED appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Medifast, Inc. (MED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
531.5×

Cheaper than 1% of US stocks

Price / sales
0.4×

Cheaper than 85% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
3.3×

Cheaper than 55% of US stocks

Growth & margins
Revenue growth (YoY)
−27.6%

Higher than 9% of US stocks

Earnings growth (YoY)
−27.6%

Higher than 16% of US stocks

Gross margin
69.9%

Higher than 82% of US stocks

Operating margin
−5.7%

Higher than 27% of US stocks

Net margin
−8.1%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−12.4%

Higher than 34% of US stocks

Return on assets
−4.6%

Higher than 32% of US stocks

Dividend yield
55.2%

Higher than 97% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPersonal Services
CompanyMarket capTKN rank
MEDMedifast, Inc.$133.6M
46
RGSRegis Corp.$66.9M
82
CSVCarriage Services, Inc.$542.6M
32
CLIKClick Holdings Ltd.$11.9M
2
LANVLanvin Group Holdings Ltd.*$131.9M
11
BRLTBrilliant Earth Group, Inc.*$134.5M
74
RENTRent the Runway, Inc.*$126.9M
27

* Nearest Consumer Cyclical names by size — few personal services companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Medifast, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MED news & analysis

Can Medifast's New Compensation Plan Accelerate Coach Growth?

Zacks Investment Research · 21 Aug 2026positive

Medifast is reshaping its coach network around Executive Directors in response to rising productivity, even as the number of active earning coaches has fallen sharply. The company is implementing a new compensation plan aimed at enhancing coach growth.

Why it matters — MED watchers would care because the restructured coach model and new compensation plan signal how the company plans to address declining active coach numbers while capitalizing on higher per-coach productivity.

Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?

Zacks Investment Research · 12 Aug 2026neutral

Zacks reports that Medifast's improving coach productivity and client retention point to stabilization, though a shrinking coach base remains a challenge for the company.

Why it matters — A MED watcher would care because coach productivity and retention gains could signal stabilization, while the declining coach base may continue to pressure the business.

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

Zacks Investment Research · 7 Aug 2026neutral

Zacks reports that Medifast's low valuation and improving coach productivity provide some potential, but a shrinking coach base and weak growth keep its turnaround effort high risk. The item frames the stock's current situation as a mix of opportunity and ongoing challenges.

Why it matters — MED watchers would care because the balance between an attractively low valuation and persistent headwinds from a declining coach base and weak growth is central to assessing the company's turnaround prospects.

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Zacks Investment Research · 7 Aug 2026positive

Medifast shares rose 13.6% over the past month, with the gains supported by improving coach productivity and higher earnings expectations, even as the company reported weaker revenue.

Why it matters — MED watchers would care because the recent share-price momentum and improved earnings outlook signal strengthening investor confidence despite softer top-line results.

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Zacks Investment Research · 7 Aug 2026neutral

Zacks reports that Medifast's Trilivy launch and cost-cutting measures could support a Q4 profit turnaround, though shrinking revenue and a declining coach base continue to pose risks.

Why it matters — A MED watcher would care because the article highlights both the potential for a Q4 profit recovery and the ongoing headwinds from falling revenue and a shrinking coach base.

FAQ

Frequently asked questions about MED stock

What is the MED stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Medifast, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MED stock a buy right now?

Of the 1 analysts covering Medifast, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medifast, Inc. 46 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MED?

As at 22 Aug 2026, Medifast, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will MED stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +0.0% from the last close, and Ticker Nerd's factor model ranks Medifast, Inc. 46 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MED stock forecast for 2030?

No analyst covering Medifast, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has MED stock performed over the past year?

Medifast, Inc. returned -16.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Medifast, Inc. do?

Medifast Inc. is a prominent player in the health and wellness industry, focused on providing scientifically developed weight management and healthy living products.

What is the latest news on MED?

The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Can Medifast's New Compensation Plan Accelerate Coach Growth?". Medifast is reshaping its coach network around Executive Directors in response to rising productivity, even as the number of active earning coaches has fallen sharply. The company is implementing a new compensation plan aimed at enhancing coach growth.

Company

About Medifast, Inc.

Medifast Inc. is a prominent player in the health and wellness industry, focused on providing scientifically developed weight management and healthy living products. With a range of offerings that include meal replacement products, snacks, and hydration solutions, the company caters to individuals seeking sustainable lifestyle transformations. Medifast reaches its customers primarily through its OPTAVIA Coaches, an integral part of their direct selling model, which offers personalized support and guidance. This unique network not only enhances customer engagement but also strengthens community-driven success. The company's innovative approach in combining nutritional science with one-on-one coaching sets it apart in the highly competitive health sector. Medifast's targeted solutions and emphasis on educational support play a significant role in the wellness revolution. As consumer interest in health-related products continues to rise, Medifast's strategies ensure its relevance and adaptability in a dynamic market, positioning it as a significant contributor to health and wellness industries globally.

CEO Mr. Nicholas M. Johnson · 380 employees · United States · https://medifastinc.com